Literature DB >> 18503258

Long-term control with etanercept (Enbrel) of a severe acrodermatitis continua of Hallopeau refractory to infliximab (Remicade).

A-M Thielen1, C Barde, G Marazza, J-H Saurat.   

Abstract

Hallopeau's acrodermatitis is characterized by the presence of aseptic pustules on an inflammatory basis of the periungual or subungual region. The cyclic recurrences induce important physical and psychological morbidity. By analogy to the efficacy of TNF-alpha antagonists in the treatment of generalized pustular psoriasis, our patient illustrates the long-term efficacy and safety of etanercept (Enbrel) in the treatment of Hallopeau's acrodermatitis refractory to infliximab (Remicade). This treatment alternative should in consequence be considered in patients with a recalcitrant form of a potentially debilitating disease. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503258     DOI: 10.1159/000134613

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Authors:  Tej Pratap Singh; Barbara Huettner; Harald Koefeler; Gerlinde Mayer; Isabella Bambach; Katrin Wallbrecht; Michael P Schön; Peter Wolf
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 2.  Autoinflammatory pustular neutrophilic diseases.

Authors:  Haley B Naik; Edward W Cowen
Journal:  Dermatol Clin       Date:  2013-06-02       Impact factor: 3.478

3.  Acrodermatitis continua of hallopeau successfully treated with adalimumab.

Authors:  Jennifer A Sopkovich; Georgann Anetakis Poulos; Henry K Wong
Journal:  J Clin Aesthet Dermatol       Date:  2012-02

4.  Acrodermatitis continua of Hallopeau: clinical perspectives.

Authors:  Mary Patricia Smith; Karen Ly; Quinn Thibodeaux; Tina Bhutani; Wilson Liao; Kristen M Beck
Journal:  Psoriasis (Auckl)       Date:  2019-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.